POXEL FRANCE Net Worth 2019-2020 | PXXLF

Interactive chart of historical net worth (market cap) for POXEL FRANCE (PXXLF) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. POXEL FRANCE net worth as of October 20, 2021 is $0.16B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.161B $0.008B
Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company's product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43